BELLUS Competitors

Delisted . USA . 
Stock . BELLUS Health
BLUDelisted Stock  USD 14.74  0.00  0.00%   
BELLUS Health competes with Terns Pharmaceuticals, Amylyx Pharmaceuticals, Acumen Pharmaceuticals, Inozyme PharmaInc, and X4 Pharmaceuticals; as well as few others. The company runs under Biotechnology sector within Health Care industry. Analyzing BELLUS Health competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of BELLUS Health to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of BELLUS Health competition on your existing holdings.
  
Specify up to 10 symbols:
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of BELLUS Health's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
14.7414.7414.74
Details
Intrinsic
Valuation
LowRealHigh
10.7710.7716.21
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as BELLUS Health. Your research has to be compared to or analyzed against BELLUS Health's peers to derive any actionable benefits. When done correctly, BELLUS Health's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in BELLUS Health.

BELLUS Health Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between BELLUS Health and its competitors represents the degree of relationship between the price movements of corresponding delisted stocks. A correlation of about +1.0 implies that the price of BELLUS and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of BELLUS Health does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
CRNX
+ 0.83
XFOR
KURA
+ 0.76
THRX
KALV
+ 0.74
AMLX
VRDN
+ 0.71
AMLX
KURA
+ 0.71
INZY
THRX
+ 0.64
INZY
  
High negative correlations   
VRDN
- 0.71
THRX
XFOR
- 0.7
AMLX
VRDN
- 0.68
XFOR
CRNX
- 0.66
AMLX
VRDN
- 0.61
CRNX
KALV
- 0.61
XFOR

Risk-Adjusted Indicators

There is a big difference between BELLUS Stock performing well and BELLUS Health Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze BELLUS Health's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
TERN  4.53 (0.38) 0.00 (0.08) 0.00 
 0.00 
 8.64 
(8.38)
 27.76 
AMLX  4.76 (1.85) 0.00 (0.37) 0.00 
 0.00 
 6.96 
(8.30)
 103.39 
ABOS  3.29 (0.20) 0.00 (0.04) 0.00 
 0.00 
 7.28 
(6.35)
 23.58 
INZY  3.76  0.12  0.05  0.09  4.48 
(4.15)
 8.83 
(8.42)
 25.32 
XFOR  4.55  0.65  0.15  0.39  4.14 
(5.93)
 10.47 
(7.00)
 35.23 
KALV  3.13 (0.12) 0.00 (0.12) 0.00 
 0.00 
 7.14 
(7.13)
 17.60 
CRNX  2.56  0.21  0.09  0.13  2.77 
(3.05)
 5.36 
(5.47)
 26.28 
THRX  2.29  1.03  0.61  1.12  0.56 
(2.92)
 4.93 
(2.71)
 53.69 
KURA  3.40  0.33  0.12  0.24  2.83 
(4.26)
 5.71 
(4.51)
 52.08 
VRDN  2.92 (0.62) 0.00 (0.24) 0.00 
 0.00 
 5.02 
(7.24)
 16.92 

BELLUS Health Competitive Analysis

The better you understand BELLUS Health competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, BELLUS Health's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across BELLUS Health's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
BLU TERN AMLX ABOS INZY XFOR KALV CRNX THRX KURA
 0.00 
 14.74 
BELLUS
 2.78 
 4.54 
Terns
 0.50 
 2.00 
Amylyx
 0.86 
 3.47 
Acumen
 4.12 
 4.65 
Inozyme
 9.09 
 1.20 
XFOR
 1.94 
 11.65 
Kalvista
 1.20 
 44.01 
Crinetics
 0.00 
 4.06 
Theseus
 3.23 
 17.99 
Kura
Market Volatility
(90 Days Market Risk)
Very steady
Moderately volatile
Very risky
Slightly risky
Slightly risky
Dangerous
Somewhat reliable
Very steady
Not too volatile
Somewhat reliable
Market Performance
(90 Days Performance)
Very Weak
Very Weak
Very Weak
Very Weak
Insignificant
Good
Very Weak
OK
Solid
Modest
Odds of Financial Distress
(Probability Of Bankruptcy)
Dangerous
Average
Low
Below Average
Above Average
High
Low
Low
Dangerous
Low
Current Valuation
(Equity Enterprise Value)
Over Valued
Under Valued
Under Valued
Under Valued
Under Valued
Under Valued
Under Valued
Fairly Valued
Over Valued
Under Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Strong Buy
Buy
Strong Buy
Strong Buy
Strong Buy
Strong Buy
Strong Buy
Not Available
Strong Buy
Trade Advice
(90 Days Macroaxis Advice)
Not Rated
Strong Sell
Strong Sell
Cautious Hold
Strong Sell
Strong Hold
Strong Sell
Hold
Not Rated
Strong Hold
Current Ratio
12.16
23.59
7.96
37.21
14.54
2.39
17.51
15.94
27.54
25.73
Net Asset
407.82 M
268.52 M
517.45 M
310.12 M
200.85 M
147.26 M
183.2 M
635.35 M
222.45 M
448.94 M
EBITDA
(72.76 M)
(101.68 M)
39.89 M
(60.95 M)
(74.35 M)
(105.53 M)
(110.24 M)
(221.51 M)
(66.44 M)
(164.96 M)
Current Valuation
1.56 B
39.09 M
(230.88 M)
(2.2 M)
157.6 M
165.74 M
433.05 M
2.53 B
(20.19 M)
1.01 B
Price To Book
3.02
1.3
0.31
0.84
2.26
4.39
5.66
6.45
0.81
3.73
Operating Margin
N/A
N/A
0.0178
N/A
N/A
N/A
N/A
-55.47
N/A
N/A
Retained Earnings
(641.84 M)
(332.63 M)
(304.95 M)
(222.8 M)
(285.93 M)
(477.9 M)
(343.08 M)
(653.7 M)
(112.19 M)
(721.44 M)
Current Asset
39.42 M
N/A
N/A
N/A
N/A
N/A
54.95 M
44.96 M
223.75 M
86.87 M
Beta
-0.28
-0.65
-0.93
0.082
1.37
0.46
0.91
0.62
3.98
0.87
Number Of Employees
74
66
384
51
59
93
118
290
38
142
Equity Positions Weight
N/A
N/A
50.03
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Shares Outstanding
126.81 M
64.65 M
67.78 M
60.08 M
61.77 M
167.94 M
42.19 M
77.93 M
44.65 M
76.18 M
Cash Flow From Operations
(77.1 M)
(67.73 M)
11.92 M
(43.06 M)
(70.67 M)
(96.51 M)
(75.26 M)
(166.31 M)
(49.63 M)
(124.82 M)
Total Debt
1.28 M
603 K
4.24 M
31.05 M
46.59 M
58.28 M
8.23 M
51.73 M
3.98 M
17.2 M
Return On Equity
-0.27
-0.34
0.13
-0.23
-0.55
-1.62
-0.79
-0.5
-0.26
-0.37
Z Score
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
26.67
N/A
Return On Asset
-0.17
-0.23
0.0534
-0.15
-0.28
-0.44
-0.42
-0.28
-0.18
-0.23
Number Of Shares Shorted
6.65 M
4.49 M
6.01 M
1.24 M
2.58 M
12.33 M
5.52 M
4.91 M
401.68 K
10.41 M
Book Value Per Share
2.91
3.95
6.52
4.61
2.27
0.31
2.56
7.91
5.17
5.34
Current Liabilities
7.73 M
N/A
N/A
N/A
N/A
N/A
4.27 M
2.41 M
11.28 M
5.05 M
Total Asset
407.82 M
268.52 M
517.45 M
310.12 M
200.85 M
147.26 M
183.2 M
635.35 M
222.45 M
448.94 M
Debt To Equity
0.002
0.01
0.036
N/A
0.02
1.28
0.054
0.009
0.018
0.013
Short Ratio
2.61
3.89
0.99
2.78
3.61
3.66
8.52
5.0
0.82
9.57
Target Price
16.05
14.21
4.25
12.8
20.33
3.55
31.6
57.92
5.25
30.25
Shares Owned By Institutions
90.41
98.15
85.76
72.61
92.95
61.32
92.21
97.18
93.28
98.25
Market Capitalization
1.87 B
301.92 M
135.56 M
210.28 M
299.59 M
221.68 M
501.2 M
3.39 B
181.28 M
1.42 B
Price To Earning
-15.27
N/A
N/A
N/A
N/A
N/A
-2.82
-12.03
737.67
-9.03
Price To Earnings To Growth
N/A
N/A
-0.15
-0.23
-0.06
N/A
N/A
N/A
N/A
N/A
Price To Sales
75790.29
302.64
0.36
538.78
N/A
53.87
107.42
865.91
N/A
N/A
Net Income
(76.08 M)
(90.21 M)
49.27 M
(52.37 M)
(71.17 M)
(101.17 M)
(92.91 M)
(214.53 M)
(56.61 M)
(152.63 M)
Earnings Per Share
-0.73
-1.27
0.7
-1.08
-1.37
-0.57
-3.12
-3.69
-1.34
-2.08
Shares Owned By Insiders
10.26
1.85
14.24
9.12
0.65
0.83
1.14
1.91
2.55
1.75
Revenue
16 K
N/A
380.79 M
N/A
N/A
N/A
N/A
4.01 M
N/A
N/A
Working Capital
340.02 M
255.49 M
382.62 M
233.64 M
181.56 M
99.21 M
157.29 M
530.21 M
190.99 M
397.22 M
Cash And Equivalents
220.14 M
139.81 M
206.68 M
189.91 M
151.48 M
47.38 M
142.08 M
408.51 M
212.43 M
450.26 M
Cash Per Share
1.75
5.51
3.53
4.69
3.77
0.69
5.78
7.6
5.55
6.73
Gross Profit
16 K
1000 K
(74.21 M)
(32.36 M)
N/A
3 M
(80.28 M)
(125.49 M)
N/A
N/A
Day Typical Price
14.74
4.54
2.0
3.47
4.65
1.2
11.65
44.01
4.06
17.99
Accumulation Distribution
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
0.0025
N/A
Market Facilitation Index
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
0.01
N/A
Daily Balance Of Power
0.0
(9,223,372,036,855)
(9,223,372,036,855)
(9,223,372,036,855)
(9,223,372,036,855)
(9,223,372,036,855)
(9,223,372,036,855)
9.2 T
N/A
(9,223,372,036,855)
Period Momentum Indicator
N/A
(0.13)
(0.01)
(0.03)
(0.20)
(0.12)
(0.23)
0.52
N/A
(0.60)
Rate Of Daily Change
1.0
0.97
1.0
0.99
0.96
0.91
0.98
1.01
1.0
0.97
Day Median Price
14.74
4.54
2.0
3.47
4.65
1.2
11.65
44.01
4.06
17.99
Price Action Indicator
N/A
(0.07)
(0.01)
(0.01)
(0.10)
(0.06)
(0.12)
0.26
(0.01)
(0.30)
Coefficient Of Variation
784.81
(2,450)
(687.65)
(5,185)
1830.44
810.2
(5,048)
1196.15
594.52
1585.93
Mean Deviation
3.16
4.53
4.76
3.29
3.76
4.55
3.13
2.56
2.29
3.4
Jensen Alpha
1.66
(0.38)
(1.85)
(0.20)
0.1232
0.6545
(0.12)
0.2074
1.03
0.3305
Total Risk Alpha
0.6664
(0.65)
(2.46)
(0.40)
(0.1)
0.302
(0.38)
0.0349
0.61
(0.07)
Sortino Ratio
0.9777
N/A
N/A
N/A
0.0464
0.1523
N/A
0.0935
0.6141
0.116
Downside Variance
2.37
N/A
N/A
N/A
20.97
20.85
N/A
8.49
2.81
9.7
Standard Deviation
12.24
5.62
11.24
4.23
4.91
6.08
4.06
3.92
6.45
6.61
Kurtosis
64.42
(0.32)
41.94
0.5472
0.8921
5.28
(0.27)
8.38
52.61
35.74
Potential Upside
2.83
8.64
6.96
7.28
8.83
10.47
7.14
5.36
4.93
5.71
Treynor Ratio
(0.64)
(0.08)
(0.37)
(0.04)
0.0871
0.3903
(0.12)
0.1309
1.12
0.2427
Maximum Drawdown
99.31
27.76
103.39
23.58
25.32
35.23
17.6
26.28
53.69
52.08
Variance
149.74
31.62
126.38
17.85
24.08
37.01
16.44
15.37
41.66
43.68
Market Risk Adjusted Performance
(0.63)
(0.07)
(0.36)
(0.03)
0.0971
0.4003
(0.11)
0.1409
1.13
0.2527
Risk Adjusted Performance
0.0898
(0.02)
(0.08)
(0)
0.0432
0.0868
(0)
0.0611
0.1151
0.0488
Skewness
7.98
0.0367
(5.69)
0.2575
0.356
1.51
0.0902
1.9
6.94
5.29
Semi Deviation
0.0
N/A
N/A
N/A
4.48
4.14
N/A
2.77
0.5598
2.83
Information Ratio
0.1229
(0.05)
(0.15)
(0.03)
0.0433
0.1143
(0.03)
0.0695
0.1596
0.0547
Value At Risk
(1.37)
(8.38)
(8.30)
(6.35)
(8.42)
(7.00)
(7.13)
(5.47)
(2.71)
(4.51)
Expected Short fall
(4.27)
N/A
N/A
N/A
(4.15)
(5.93)
N/A
(3.05)
(2.92)
(4.26)
Downside Deviation
1.54
N/A
N/A
N/A
4.58
4.57
N/A
2.91
1.68
3.12
Semi Variance
(0.52)
N/A
N/A
N/A
20.06
17.18
N/A
7.67
0.3133
8.04

BELLUS Health Competition Performance Charts

Five steps to successful analysis of BELLUS Health Competition

BELLUS Health's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by BELLUS Health in relation to its competition. BELLUS Health's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of BELLUS Health in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact BELLUS Health's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to BELLUS Health, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your BELLUS Health position

In addition to having BELLUS Health in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Large Growth Funds Thematic Idea Now

Large Growth Funds
Large Growth Funds Theme
Funds or Etfs that invest in stocks of large-sized companies with above-average risk and growth rate. The Large Growth Funds theme has 40 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Large Growth Funds Theme or any other thematic opportunities.
View All  Next Launch
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.
You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.

Other Consideration for investing in BELLUS Stock

If you are still planning to invest in BELLUS Health check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the BELLUS Health's history and understand the potential risks before investing.
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY